N/A
Completed N=5
Infrared and Broadband Light for Skin Aging
Source: ClinicalTrials.gov NCT03243981 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcomePrimary: Number of Genes With Significant Change in Gene Transcription — 188; 45 genes
Summary
In this exploratory study, we hope to learn if treatment of broadband light with infrared light can alter the molecular pathways associated with aging. Secondary exploratory objective is to see if there are any visible effects of this light treatment on human skin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Genes With Significant Change in Gene Transcription |
188; 45 | — |
| SECONDARY Change From Baseline in Fine Wrinkling Score as a Measure of Skin Rejuvenation |
7.8; 7.5; 5.0; 5.3 | — |
| SECONDARY Change From Baseline in Coarse Wrinkling Score as a Measure of Skin Rejuvenation |
5.0; 6.0; 2.3; 2.5 | — |
| SECONDARY Change From Baseline in Sagging Score as a Measure of Skin Rejuvenation |
7.0; 7.5; 3.5; 4.3 | — |
| SECONDARY Change From Baseline in Physician Global Assessment as a Measure of Skin Rejuvenation |
8.3; 8.3; 5.5; 6.0 | — |
| SECONDARY Change From Baseline in Cutometry as a Measure of Skin Rejuvenation |
— | — |
| SECONDARY Change From Baseline in Transepidermal Water Loss as a Measure of Skin Rejuvenation |
— | — |
Eligibility Criteria
Inclusion Criteria
- 1. Female 2. Age 55 years or older (total 6) 3. Fitzpatrick skin type 2-3 4. Photo-aging at least moderate on the extensor forearms
Exclusion Criteria
- 1. Unable to understand and sign informed consent form 2. Unable to comply with study procedures 3. Pregnant or lactating 4. Prior treatment to forearms including topical retinoid, laser treatment, photodynamic treatment, prescription topical agents x 1 month 5. Active skin conditions that precluding treatment including zoster, blistering skin disease, psoriasis, atopic dermatitis, abnormal scarring, skin cancer in the area of study treatment 6. Currently on hormone based therapy (both systemic and topical)
Data sourced from ClinicalTrials.gov (NCT03243981). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.